Five microRNAs in plasma as novel biomarkers for screening of early-stage non-small cell lung cancer

Respiratory Research

Table 4 Subgroup analysis of predictive value for the 5 identified miRNAs in validation set

MiRNAs	NSCLC vs. Healthy			NSCLC vs. NCPD			NCPD vs. Healthy
MiRNAs	SEN	SPE	AUC	SEN	SPE	AUC	SEN	SPE	AUC
miR-20a	0.81	0.85	0.91	0.81	0.81	0.86	0.60	0.63	0.61
Smokers	0.89	0.89	0.98	0.85	0.85	0.94	0.64	0.52	0.61
Non-smokers	0.63	0.63	0.64	0.70	0.73	0.75	0.66	0.67	0.68
Stage I	0.77	0.76	0.84	0.76	0.76	0.77	0.63	0.59	0.61
Stage II	0.98	0.98	0.99	0.98	0.97	0.99	0.60	0.59	0.61
AC	0.87	0.83	0.90	0.84	0.81	0.85	0.61	0.59	0.62
SC	0.97	0.97	0.98	0.92	0.90	0.98	0.63	0.59	0.60
miR-223
Smokers	0.85	0.85	0.94	0.93	0.90	0.98	0.65	0.65	0.69
Non-smokers	0.78	0.78	0.93	0.78	0.75	0.89	0.72	0.75	0.73
Stage I	0.72	0.70	0.86	0.65	0.64	0.70	0.65	0.64	0.67
Stage II	0.97	0.97	0.98	0.94	0.95	0.98	0.65	0.64	0.67
AC	0.80	0.82	0.91	0.73	0.71	0.77	0.65	0.62	0.67
SC	0.95	0.93	0.98	0.92	0.93	0.98	0.65	0.64	0.67
miR-21
Smokers	0.83	0.81	0.87	0.78	0.75	0.84	0.63	0.63	0.64
Non-smokers	0.55	0.50	0.57	0.53	0.52	0.55	0.57	0.58	0.59
Stage I	0.67	0.67	0.69	0.57	0.57	0.61	0.56	0.57	0.58
Stage II	0.87	0.88	0.96	0.88	0.88	0.95	0.57	0.56	0.58
AC	0.60	0.60	0.63	0.51	0.50	0.56	0.57	0.57	0.58
SC	0.91	0.90	0.97	0.92	0.90	0.97	0.56	0.57	0.58
miR-155
Smokers	0.86	0.82	0.88	0.78	0.76	0.88	0.52	0.51	0.53
Non-smokers	0.91	0.93	0.98	0.89	0.88	0.98	0.65	0.63	0.64
Stage I	0.80	0.80	0.91	0.76	0.76	0.84	0.55	0.52	0.59
Stage II	0.94	0.95	0.97	0.83	0.83	0.95	0.55	0.52	0.60
AC	0.87	0.87	0.93	0.80	0.78	0.86	0.55	0.52	0.59
SC	0.92	0.90	0.96	0.81	0.81	0.93	0.52	0.52	0.59
miR-145
Smokers	0.96	0.96	0.98	0.95	0.90	0.97	0.57	0.58	0.68
Non-smokers	0.81	0.84	0.90	0.63	0.62	0.79	0.60	0.62	0.63
Stage I	0.59	0.57	0.62	0.51	0.50	0.55	0.52	0.52	0.58
Stage II	0.91	0.90	0.96	0.76	0.73	0.87	0.52	0.52	0.58
AC	0.71	0.70	0.77	0.57	0.55	0.59	0.55	0.50	0.58
SC	0.95	0.95	0.97	0.79	0.79	0.89	0.52	0.52	0.58

ISSN: 1465-993X